The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

In today’s fast-paced world, maintaining optimal nerve health is paramount for overall well-being. Nerve-related issues can ...

But the Boston drugmaker’s share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs.

But the Boston drugmaker's share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs.

But the Boston drugmaker's share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs.

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

2024 — Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin that drives childbirth ... Neuropathic Pain ...